Larbouret, C., Gaborit, N., Chardès, T., Coelho, M., Campigna, E., Bascoul-Mollevi, C., . . . Pèlegrin, A. (2012). In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption. Neoplasia Press Inc.
Chicago-stil citatLarbouret, Christel, et al. In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting With Cetuximab/Trastuzumab Is More Effective Than Treatment With Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption. Neoplasia Press Inc, 2012.
MLA-referensLarbouret, Christel, et al. In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting With Cetuximab/Trastuzumab Is More Effective Than Treatment With Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption. Neoplasia Press Inc, 2012.